RHUMBLINE ADVISERS

Position in CLLS — Cellectis S.A.

CIK 1115418 BOSTON, MA

Position in CLLS

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$47,819

-$16,761 QoQ

Shares Held

15,085

+13.1% QoQ

Ownership

0.015%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. CLLS ranks #238 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$47,819	15,085	+13.1%	Shares	Sole	2026-05-12
2025-12-31	$64,580	13,343	+817.0%	Shares	Sole	2026-02-13
2025-09-30	$4,146	1,455	-23.6%	Shares	Sole	2025-11-06
2025-06-30	$2,905	1,905	-9.9%	Shares	Sole	2025-08-12
2025-03-31	$2,622	2,115	0.0%	Shares	Sole	2025-05-29
2024-12-31	$3,807	2,115	-45.1%	Shares	Sole	2025-05-29
2024-09-30	$8,172	3,855	0.0%	Shares	Sole	2024-11-12
2024-06-30	$7,208	3,855	0.0%	Shares	Sole	2024-08-01
2024-03-31	$10,215	3,855	0.0%	Shares	Sole	2024-05-09
2023-12-31	$11,873	3,855	+29.8%	Shares	Sole	2024-02-08
2023-09-30	$4,692	2,970	0.0%	Shares	Sole	2023-11-09
2023-06-30	$5,844	2,970	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.